Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

Abstract

The blood–brain barrier (BBB) is a continuous endothelial membrane within brain microvessels that has sealed cell-to-cell contacts, and is sheathed by mural vascular cells and perivascular astrocyte end-feet. The BBB protects neurons from factors present in the systemic circulation, and maintains the highly regulated CNS internal milieu, which is required for proper synaptic and neuronal functioning. BBB disruption allows influx into the brain of neurotoxic blood-derived debris, cells, and microbial pathogens, and is associated with inflammatory and immune responses, which can initiate multiple pathways of neurodegeneration. This Review discusses neuroimaging studies in the living human brain, post-mortem tissue and biomarker studies demonstrating BBB breakdown in Alzheimer disease, Parkinson disease, Huntington disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV-1-associated dementia and chronic traumatic encephalopathy. The pathogenic mechanisms by which BBB breakdown leads to neuronal injury, synaptic dysfunction, loss of neuronal connectivity and neurodegeneration are described. The importance of a healthy BBB for therapeutic drug delivery, and the adverse effects of disease-initiated, pathological BBB breakdown in relation to brain delivery of neuropharmaceuticals are briefly discussed. Finally, future directions, gaps in the field and opportunities to control the course of neurological diseases by targeting BBB are presented.

Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA

“…The pathogenesis underlying neurodegenerative disease is accompanied by a series of pathophysiological events such as axonal degeneration, synapse loss, dendritic retraction (Sweeney, et al, 2018; Yates, 2012) and the propagation of misfolded proteins (Raj et al, 2012; Yates, 2012). These events impact structural and functional properties to different extents in different regions.…”

Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review

“…In addition to MRS, several other imaging markers exist. Blood-brain barrier (BBB) permeability is associated with neuroimmune activation [75, 76] and can be imaged with MR and PET methods. However, abused substances that exert neuroimmune effects via mechanisms unrelated to BBB permeability, i.e.…”

Toward in vivo determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis

“…Although ALS is considered primarily a degenerative disorder, neuroinflammation has additionally been suggested to contribute to the pathobiology . Reports of several human and animal studies have described inflammation in ALS, such as postmortem evidence of glial activation and blood–brain/–spinal cord barrier integrity loss . There is, moreover, immune activation of the peripheral nervous system (PNS) in the superoxide dismutase 1 (SOD1) transgenic mouse model of ALS …”

“…Our retrospective cohort study sought to test the hypothesis that patients with ALS may be classified into suspected PNS degeneration vs. PNS inflammation constellations on the basis of their upper limb CSA. This was tested by combining results of nerve ultrasound with the patients’ cerebrospinal fluid (CSF) albumin/serum albumin ratio (Q alb ); the latter is the best established in vivo measure of blood–CSF barrier integrity and is commonly taken as a surrogate marker of blood–brain/–nerve barrier leakage that is thought to be indicative of inflammatory and immune response …”